Sylvia A. Holden

5.3k total citations · 2 hit papers
85 papers, 4.4k citations indexed

About

Sylvia A. Holden is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Sylvia A. Holden has authored 85 papers receiving a total of 4.4k indexed citations (citations by other indexed papers that have themselves been cited), including 41 papers in Molecular Biology, 34 papers in Oncology and 33 papers in Cancer Research. Recurrent topics in Sylvia A. Holden's work include Cancer, Hypoxia, and Metabolism (24 papers), Cancer therapeutics and mechanisms (10 papers) and Cancer-related Molecular Pathways (10 papers). Sylvia A. Holden is often cited by papers focused on Cancer, Hypoxia, and Metabolism (24 papers), Cancer therapeutics and mechanisms (10 papers) and Cancer-related Molecular Pathways (10 papers). Sylvia A. Holden collaborates with scholars based in United States, Germany and Japan. Sylvia A. Holden's co-authors include Beverly A. Teicher, Terence S. Herman, E Frei, H. Phillip Koeffler, Bruce M. Spiegelman, Lan Bo Chen, Daniel J. DeAngelo, Samuel Singer, Pasha Sarraf and Elisabetta Mueller and has published in prestigious journals such as Science, Journal of Clinical Investigation and Nature Medicine.

In The Last Decade

Sylvia A. Holden

84 papers receiving 4.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Differentiation and reversal of malignant changes in colon cancer through PPARγ

1998 865 citations Sylvia A. Holden et al. profile →
Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo.

1998 534 citations Sylvia A. Holden et al. PubMed profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sylvia A. Holden United States	31	2.8k	1.6k	1.4k	507	398	85	4.4k
Stephen Gately United States	24	2.0k 0.7×	1.2k 0.7×	675 0.5×	557 1.1×	343 0.9×	40	3.5k
Timothy Madden United States	37	2.1k 0.7×	714 0.4×	1.6k 1.2×	407 0.8×	368 0.9×	108	4.8k
Graziella Pratesi Italy	42	3.7k 1.3×	1.1k 0.7×	3.9k 2.8×	340 0.7×	532 1.3×	147	6.7k
Oliver Stoeltzing United States	43	3.0k 1.1×	1.4k 0.9×	1.6k 1.1×	186 0.4×	538 1.4×	73	4.6k
Daniel C. Chan United States	42	3.0k 1.0×	622 0.4×	1.6k 1.2×	602 1.2×	1.4k 3.5×	82	5.3k
Steffen Hauptmann Germany	42	2.1k 0.7×	1.0k 0.6×	1.4k 1.0×	432 0.9×	634 1.6×	111	4.9k
Niramol Savaraj United States	47	3.2k 1.1×	1.7k 1.1×	2.4k 1.7×	155 0.3×	741 1.9×	211	6.9k
Francis Ali‐Osman United States	43	4.2k 1.5×	1.3k 0.8×	2.0k 1.5×	141 0.3×	457 1.1×	140	6.7k
David G. Menter United States	43	2.1k 0.7×	1.4k 0.9×	2.6k 1.9×	598 1.2×	984 2.5×	136	5.9k
Joan M. Carboni United States	34	2.4k 0.9×	804 0.5×	1.4k 1.0×	185 0.4×	361 0.9×	75	4.0k

Countries citing papers authored by Sylvia A. Holden

Since Specialization

Citations

This map shows the geographic impact of Sylvia A. Holden's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sylvia A. Holden with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sylvia A. Holden more than expected).

Fields of papers citing papers by Sylvia A. Holden

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sylvia A. Holden. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sylvia A. Holden. The network helps show where Sylvia A. Holden may publish in the future.

Co-authorship network of co-authors of Sylvia A. Holden

This figure shows the co-authorship network connecting the top 25 collaborators of Sylvia A. Holden. A scholar is included among the top collaborators of Sylvia A. Holden based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sylvia A. Holden. Sylvia A. Holden is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kumar, Ashok, David Brennan, Sylvia A. Holden, et al.. (2017). Abstract 3221: Kevetrin induces p53-dependent and independent cell cycle arrest and apoptosis in ovarian cancer cell lines representing heterogeneous histologies. Cancer Research. 77(13_Supplement). 3221–3221. 3 indexed citations

Shapiro, Geoffrey I., James W. Mier, John Hilton, et al.. (2015). A phase 1, dose-escalation, safety, pharmacokinetic, pharmacodynamic study of thioureidobutyronitrile, a novel p53 targeted therapy, in patients with advanced solid tumors.. Journal of Clinical Oncology. 33(15_suppl). TPS2613–TPS2613. 2 indexed citations

Holden, Sylvia A., et al.. (1997). Host distribution and response to antitumor alkylating agents of EMT-6 tumor cells from subcutaneous tumor implants. Cancer Chemotherapy and Pharmacology. 40(1). 87–93. 11 indexed citations

Holden, Sylvia A., Beverly A. Teicher, Michael F. Robinson, David Northey, & A. Rosowsky. (1995). Antifolates can potentiate topoisomerase II inhibitors in vitro and in vivo. Cancer Chemotherapy and Pharmacology. 36(2). 165–171. 14 indexed citations

Teicher, Beverly A., Sylvia A. Holden, Gulshan Ara, et al.. (1995). Influence of an anti‐angiogenic treatment on 9L gliosarcoma: Oxygenation and response to cytotoxic therapy. International Journal of Cancer. 61(5). 732–737. 98 indexed citations

Teicher, Beverly A., Timothy Korbut, Krishna Menon, Sylvia A. Holden, & Gulshan Ara. (1994). Cyclooxygenase and lipoxygenase inhibitors as modulators of cancer therapies. Cancer Chemotherapy and Pharmacology. 33(6). 515–522. 56 indexed citations

Holden, Sylvia A., Beverly A. Teicher, & Emil Frei. (1994). Long-term persistence and cytokinetics of human tumor cells in vitro following high-dose alkylating agent exposure. Cancer Letters. 87(2). 211–222. 2 indexed citations

Frei, E, Sylvia A. Holden, René Gonin, David J. Waxman, & Beverly A. Teicher. (1993). Antitumor alkylating agents: in vitro cross-resistance and collateral sensitivity studies. Cancer Chemotherapy and Pharmacology. 33(2). 113–122. 19 indexed citations

Teicher, Beverly A., et al.. (1993). Addition of a topoisomerase I inhibitor to trimodality therapy [cis-diamminedichloroplatinum(II)/heat/radiation] in a murine tumor. Journal of Cancer Research and Clinical Oncology. 119(11). 645–651. 10 indexed citations

10.

Teicher, Beverly A., Sylvia A. Holden, David Northey, Mark W. Dewhirst, & Terence S. Herman. (1993). Therapeutic effect of infused fluosol-da/carbogen with ephedrine, flunarizine, or nitroprusside. International Journal of Radiation Oncology*Biology*Physics. 26(1). 103–109. 10 indexed citations

11.

Teicher, Beverly A., Sylvia A. Holden, Gulshan Ara, et al.. (1992). Effect of a Bovine Hemoglobin Preparation (Sbhs) on the Response of Two Murine Solid Tumors to Radiation Therapy or Chemotherapeutic Alkylating Agents. Biomaterials Artificial Cells and Immobilization Biotechnology. 20(2-4). 657–660. 21 indexed citations

12.

Teicher, Beverly A., et al.. (1991). Effect of oxygenation, pH and hyperthermia on RSU-1069 in vitro and in vivo with radiation in the FSaIIC murine fibrosarcoma. Cancer Letters. 59(2). 109–117. 4 indexed citations

13.

Eder, Joseph P., et al.. (1990). Ability of four potential topoisomerase II inhibitors to enhance the cytotoxicity ofcis-diamminedichloroplatinum (II) in Chinese hamster ovary cells and in an epipodophyllotoxin-resistant subline. Cancer Chemotherapy and Pharmacology. 26(6). 423–428. 19 indexed citations

14.

Teicher, Beverly A., Thomas C. Shea, Sylvia A. Holden, et al.. (1989). Cross-resistance and glutathione-S-transferase-pi levels among four human melanoma cell lines selected for alkylating agent resistance.. PubMed. 49(22). 6185–92. 82 indexed citations

15.

Teicher, Beverly A., TS Herman, Sylvia A. Holden, & Steven M. Jones. (1989). Addition of Misonidazole, Etanidazole, or Hyperthermia to Treatment With Fluosol-DA/Carbogen/Radiation. JNCI Journal of the National Cancer Institute. 81(12). 929–934. 17 indexed citations

16.

Teicher, Beverly A., Sylvia A. Holden, Steven J.M. Jones, Joseph P. Eder, & Terence S. Herman. (1989). Influence of scheduling on two-drug combinations of alkylating agents in vivo. Cancer Chemotherapy and Pharmacology. 25(3). 161–166. 16 indexed citations

17.

Eder, Joseph P., Karen H. Antman, Anthony Elias, et al.. (1988). Cyclophosphamide and Thiotepa With Autologous Bone Marrow Transplantation in Patients With Solid Tumors. JNCI Journal of the National Cancer Institute. 80(15). 1221–1226. 42 indexed citations

18.

Teicher, Beverly A., Terence S. Herman, & Sylvia A. Holden. (1988). Combined modality therapy with bleomycin, hyperthermia, and radiation.. PubMed. 48(22). 6291–7. 30 indexed citations

19.

Teicher, Beverly A. & Sylvia A. Holden. (1987). Survey of the effect of adding Fluosol-DA 20%/O2 to treatment with various chemotherapeutic agents.. PubMed. 71(2). 173–7. 21 indexed citations

20.

Teicher, Beverly A. & Sylvia A. Holden. (1987). Antitumor and Radiosensitizing Activity of Several Platinum-(+) Dye Complexes. Radiation Research. 109(1). 58–58. 27 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact